# BPC-157 TB-500: The Wolverine Two-Peptide Blend, Set Down for the Record

> BPC-157 TB-500 is the Wolverine blend — two synthetic peptides paired as a tissue-repair stack. Here is what each component's research measured, why they are combined, and where the combination evidence stops.

The Wolverine blend sets two synthetic peptides side by side: BPC-157, the cytoprotective and pro-angiogenic component, and TB-500, the actin-binding cell-migration component. Each carries its own measured record. The pairing between them is kept in the warm margin, because no controlled combination study exists.

## Two peptides, set down as two specimen plates

BPC-157 TB-500 is not one molecule. It is a research-community pairing of two distinct synthetic peptides, sold and discussed under the name Wolverine. This reading-room keeps it the way a careful apothecary would keep a formulary entry: two specimens drawn on their own plates, each annotated to its own studies, with the join between them noted honestly rather than smoothed over.

The first specimen is BPC-157 (Body Protection Compound 157), a 15-amino-acid pentadecapeptide, sequence `Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val` (`GEPPPGKPADDAGLV`), molecular weight `~1419.53 Da`, derived from a protein found in human gastric juice. Its role in the pairing is the local cytoprotective and pro-angiogenic signal: it up-regulates VEGFR2 and activates the VEGFR2-Akt-eNOS pathway [2].

The second specimen is TB-500, a synthetic N-acetylated heptapeptide, `Ac-LKKTETQ`, molecular weight `~889.02 Da`, corresponding to residues 17-23 — the actin-binding region — of the 43-residue protein Thymosin Beta-4. Its role is the cytoskeletal signal: the `LKKTETQ` motif binds monomeric G-actin and regulates the actin dynamics that drive cell migration [3]. One caveat belongs on the plate from the start: most efficacy data filed under the name TB-500 were generated with full-length Thymosin Beta-4, a far larger molecule than the heptapeptide actually in the vial [5].

The rest of this record follows those two plates. The [BPC-157 and TB-500 benefits for tendon and tissue recovery](/recovery-research) page keeps the repair findings; [the combination rationale and synergy claim](/research) reads the two mechanisms together; the [BPC-157 TB-500 dosage in the research literature](/dosage) keeps the research-context dose figures and the [half-life and reconstitution of the blend](/dosage); and the [Wolverine legal status and FDA 503A compounding access](/legal-status) page keeps the regulatory record. For the short answers, see the [frequently asked questions about the blend](/faq).

## What the Wolverine peptide blend is

The Wolverine peptide blend is a research-community name for the two-peptide pairing of BPC-157 and TB-500, marketed and discussed as a tissue-repair stack. It is not a single chemical entity and not an approved product. It has no single molecular weight, no CAS number, and no standardized composition — commercial vials commonly print a combined per-vial mass, for example `10 mg` BPC-157 with `10 mg` TB-500, but no ratio is clinically validated.

The value of treating it as two specimens rather than one product is that the evidence sorts cleanly that way. BPC-157 has its own animal-model literature; Thymosin Beta-4, the parent of the TB-500 fragment, has its own. The blend inherits both — and inherits both of their gaps.

### BPC 157 TB 500 at a glance {#bpc-157-tb-500-at-a-glance}

BPC 157 TB 500 is the unhyphenated surface form of the same blend, and the chemistry does not change with the punctuation. BPC-157 stays the `~1419.53 Da` pentadecapeptide; TB-500 stays the `~889.02 Da` `Ac-LKKTETQ` heptapeptide. Both are supplied as lyophilized powders for research use, both are studied predominantly in rodents, and both are prohibited by the World Anti-Doping Agency. Neither is an FDA-approved drug, and the combination has never been tested in a controlled human trial [7].

### What is the Wolverine peptide blend?

A research-community name for a two-peptide pairing of BPC-157 and TB-500, marketed and discussed as a tissue-repair stack. It is not a single chemical entity or an approved product, and no standardized composition or ratio is clinically validated. The consolidated Thymosin Beta-4 literature is one of its two evidence sources [4].

### What is the difference between BPC-157 and TB-500?

BPC-157 is a 15-amino-acid pentadecapeptide (`~1419.53 Da`) derived from a gastric-juice protein, acting via VEGFR2-Akt-eNOS angiogenic signaling [2]. TB-500 is a 7-amino-acid acetylated fragment (`Ac-LKKTETQ`, `~889.02 Da`) of Thymosin Beta-4 that sequesters G-actin to regulate cell migration [3]. They differ in structure, size, and mechanism.

## BPC-157 and TB-500: the two peptides in the Wolverine blend

BPC-157 and TB-500 are paired on a complementary-mechanism rationale: BPC-157 supplies a local, vessel-facing signal, while TB-500 supplies an intracellular, cytoskeleton-facing signal. The two are described as acting through largely non-overlapping pathways, which is the basis of the marketed synergy claim.

The separate halves are genuinely characterized. BPC-157 accelerated healing of a fully transected rat Achilles tendon across biomechanical, functional, microscopic, and macroscopic measures, and in vitro reversed growth inhibition of tendocytes into stimulation [1]. Thymosin Beta-4, TB-500's parent protein, binds actin, promotes cell migration and stem-cell activity, decreases scar-forming myofibroblasts, and promotes angiogenesis [4].

The join is the part that is not characterized. No peer-reviewed study defines a synergy ratio, dose, or endpoint for the two peptides given together [7]. On these plates, each specimen is drawn fully; the line connecting them into a combined effect is the warm-margin note that says "not yet measured."

### Using BPC-157 with TB-500 in research models {#bpc-157-with-tb-500}

BPC-157 with TB-500 is the pairing read as a research-model construct rather than a validated combination. The rationale is that a pro-angiogenic, cytoprotective signal [2] plus an actin-sequestration, pro-migration signal [3] would cover more of the repair cascade than either alone. That logic is reasonable on paper, but it remains an extrapolation from two independently studied mechanisms — no controlled head-to-head or combination study has tested it [7]. The 2025 systematic review of BPC-157 in orthopaedic sports medicine makes no mention of TB-500 or combination use at all [7].

### The Wolverine 'stack' framing {#bpc-157-tb-500-stack}

The BPC-157 TB-500 stack is the same pairing under the community term stack — a label, not an approved formulation. Commercial Wolverine vials are often labeled with a combined per-vial mass, for example `10 mg` BPC-157 with `10 mg` TB-500, but no standardized composition or ratio is clinically validated, and product identity and purity in unregulated material are not guaranteed. The stack inherits each component's evidence and each component's gaps.

### Why are BPC-157 and TB-500 combined (the Wolverine stack)?

The rationale is complementary mechanisms — BPC-157 supplies a local angiogenic and cytoprotective signal while TB-500 supplies an actin-sequestration and cell-migration signal — but this synergy is a theoretical extrapolation, not a finding from a controlled combination study [7]. The two pathways are largely non-overlapping [2] [3].

## What the blend is used for in research

In animal models, the two constituents are studied separately for tissue repair. The BPC-157 work centers on tendon, ligament, and muscle [1]; the TB-500 / Thymosin Beta-4 work centers on cell migration, wound re-epithelialization, reduced scarring, and angiogenesis [4]. Every one of those is a single-component result in a non-human model. None is a combination result, and none is a human result for the blend.

That distinction is the whole reason this reading-room keeps two plates instead of one panel. The benefits attributed to the Wolverine blend are the sum of two separate animal-model literatures, presented together, with the join drawn as an open question [7]. The research page reads the two mechanisms in full and keeps [human clinical evidence and the data gap](/research) in plain view.

### What is BPC-157 and TB-500?

BPC-157 is a synthetic 15-amino-acid pentadecapeptide (the cytoprotective and angiogenic component); TB-500 is a synthetic `Ac-LKKTETQ` heptapeptide from the actin-binding region of Thymosin Beta-4 (the cytoskeletal and cell-migration component) [3]. The Wolverine blend pairs the two. Neither is an FDA-approved drug.

### What is the BPC-157 and TB-500 blend used for in research?

In animal models the constituents have been studied for tendon, ligament, muscle, and wound repair [1] [4]. All efficacy data are preclinical and single-compound, not from the blend in humans — there is no controlled combination study of any kind [7].

---

The Wolverine blend kept as a kiln-fired formulary entry — BPC-157 and TB-500 set down as two annotated specimens, their measured animal-model findings inked and their unproven join left in the warm margin, with the FDA 503A and WADA record pinned to the page and nothing here prescribed or sold.